X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2645) 2645
Publication (216) 216
Book Review (76) 76
Book Chapter (30) 30
Book / eBook (16) 16
Conference Proceeding (5) 5
Magazine Article (4) 4
Dissertation (2) 2
Data Set (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2027) 2027
index medicus (1527) 1527
male (1215) 1215
female (1151) 1151
middle aged (898) 898
aged (820) 820
hypertension (816) 816
angiotensin (761) 761
angiotensin-converting enzyme inhibitors - therapeutic use (760) 760
risk factors (534) 534
adult (495) 495
hypertension - drug therapy (487) 487
mortality (464) 464
cardiac & cardiovascular systems (439) 439
animals (426) 426
heart failure (421) 421
pharmacology & pharmacy (404) 404
treatment outcome (393) 393
antihypertensive agents - therapeutic use (379) 379
angiotensin ii type 1 receptor blockers - therapeutic use (374) 374
drug therapy (343) 343
renin-angiotensin system (328) 328
enzymes (310) 310
analysis (301) 301
care and treatment (298) 298
blood pressure (297) 297
medicine & public health (286) 286
diabetes (285) 285
blood-pressure (280) 280
peripheral vascular disease (280) 280
aged, 80 and over (276) 276
research (252) 252
adrenergic beta-antagonists - therapeutic use (249) 249
retrospective studies (242) 242
heart failure - drug therapy (239) 239
risk (239) 239
health aspects (230) 230
internal medicine (222) 222
blood pressure - drug effects (218) 218
drug therapy, combination (214) 214
ace inhibitors (213) 213
angiotensin-ii (211) 211
urology & nephrology (209) 209
medicine, general & internal (207) 207
cardiology (203) 203
renin-angiotensin system - drug effects (200) 200
enzyme inhibitors (199) 199
angiotensin receptor antagonists - therapeutic use (196) 196
angiotensin ii (195) 195
prevention (195) 195
kidney diseases (192) 192
hypertension - physiopathology (189) 189
medicine (183) 183
angiotensin-converting enzyme inhibitors (180) 180
prospective studies (180) 180
disease (178) 178
patients (176) 176
cardiovascular disease (175) 175
follow-up studies (173) 173
management (171) 171
time factors (170) 170
diuretics - therapeutic use (165) 165
prognosis (165) 165
medical research (163) 163
diuretics (162) 162
hypertension - complications (161) 161
studies (158) 158
therapy (158) 158
rats (155) 155
endocrinology & metabolism (151) 151
cardiovascular (150) 150
abridged index medicus (145) 145
cardiovascular diseases (144) 144
calcium channel blockers - therapeutic use (143) 143
myocardial-infarction (142) 142
prevalence (141) 141
antihypertensive drugs (139) 139
heart failure - physiopathology (139) 139
renin (139) 139
tetrazoles - therapeutic use (139) 139
cohort studies (137) 137
angiotensin-converting enzyme inhibitors - adverse effects (134) 134
diagnosis (134) 134
diabetes mellitus (133) 133
drugs (133) 133
heart-failure (133) 133
research article (132) 132
nephrology (128) 128
disease progression (127) 127
chronic kidney disease (126) 126
chronic kidney failure (126) 126
heart (126) 126
medicine, experimental (126) 126
aldosterone (125) 125
survival (125) 125
angiotensin receptor antagonists (124) 124
angiotensin-converting enzyme (124) 124
cardiac patients (124) 124
clinical trials (124) 124
outcomes (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2670) 2670
Japanese (20) 20
German (5) 5
Spanish (3) 3
Chinese (2) 2
French (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annual Review of Pharmacology and Toxicology, ISSN 0362-1642, 1/2015, Volume 55, Issue 1, pp. 333 - 352
The four major classes of antihypertensive drugs-diuretics, β-blockers, calcium channel blockers, and renin-angiotensin system inhibitors (including... 
angiotensin-converting enzyme inhibitors | β-blockers | angiotensin receptor blockers | calcium channel blockers | diuretics | hypertension | Angiotensin-converting enzyme inhibitors | Hypertension | Diuretics | Calcium channel blockers | Angiotensin receptor blockers | CLINICAL-PHARMACOLOGY | CARDIOVASCULAR EVENTS | HEART-FAILURE | beta-blockers | CONVERTING ENZYME-INHIBITORS | BLOOD-PRESSURE REDUCTION | CANADIAN HYPERTENSION | CALCIUM-CHANNEL BLOCKERS | ANGIOTENSIN-RECEPTOR BLOCKERS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CORONARY-ARTERY-DISEASE | Adrenergic beta-Antagonists - classification | Angiotensin-Converting Enzyme Inhibitors - classification | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Treatment Outcome | Structure-Activity Relationship | Antihypertensive Agents - classification | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - chemistry | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers - classification | Hypertension - complications | Calcium Channel Blockers - classification | Diuretics - therapeutic use | Blood Pressure - drug effects | Molecular Structure | Diuretics - classification | Adrenergic beta-Antagonists - therapeutic use | Index Medicus
Journal Article
Cardiovascular and Hematological Agents in Medicinal Chemistry, ISSN 1871-5257, 01/2006, Volume 4, Issue 1, pp. 67 - 73
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2005, Volume 352, Issue 6, pp. 558 - 569
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9647, pp. 1394 - 1402
Summary Background Results of previous studies suggest that renin-angiotensin system blockers might reduce the burden of diabetic retinopathy. We therefore... 
Internal Medicine | MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | RENIN-ANGIOTENSIN SYSTEM | CARDIOVASCULAR-DISEASE | COMPLICATIONS | LISINOPRIL | BLOOD-FLOW | HYPERTENSION | FAILURE | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Diabetic Retinopathy - drug therapy | Angiotensin II Type 1 Receptor Blockers - adverse effects | Double-Blind Method | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Retinopathy - classification | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - complications | Diabetes Mellitus, Type 1 - drug therapy | Adolescent | Adult | Female | Tetrazoles - therapeutic use | Diabetic Retinopathy - etiology | Tetrazoles - adverse effects | Benzimidazoles - adverse effects | Insulin - therapeutic use | Benzimidazoles - therapeutic use | Prevention | Diabetic retinopathy | Complications and side effects | Candesartan | Type 1 diabetes | Dosage and administration | Drug therapy | Risk factors | Studies | Clinical trials | Photographs | Diabetes | Pressure measurement | Patients | Index Medicus | Abridged Index Medicus | Benzimidazoles | Tetrazoles | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | Hypoglycemic Agents | MEDICAL AND HEALTH SCIENCES | Type 1 | drug therapy | complications | Diabetes Mellitus | classification | Insulin | etiology | adverse effects | therapeutic use | Diabetic Retinopathy
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2016, Volume 2016, Issue 1, p. CD009210
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9647, pp. 1385 - 1393
Summary Background Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow... 
Internal Medicine | MORTALITY | MEDICINE, GENERAL & INTERNAL | LOSARTAN | RISK-FACTORS | RENIN | DISEASE | BLOOD-PRESSURE CONTROL | ANGIOTENSIN-II | ARTERY | HYPERTENSION | ENDOTHELIAL GROWTH-FACTOR | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Diabetic Retinopathy - drug therapy | Angiotensin II Type 1 Receptor Blockers - adverse effects | Double-Blind Method | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Retinopathy - classification | Hypertension - drug therapy | Male | Dose-Response Relationship, Drug | Endpoint Determination | Hypertension - complications | Adult | Female | Tetrazoles - therapeutic use | Aged | Diabetic Retinopathy - etiology | Tetrazoles - adverse effects | Benzimidazoles - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Benzimidazoles - therapeutic use | Type 2 diabetes | Diabetic retinopathy | Complications and side effects | Candesartan | Dosage and administration | Drug therapy | Risk factors | Heart attacks | Eye diseases | Photographs | Diabetes | Patients | Index Medicus | Abridged Index Medicus | Benzimidazoles | Tetrazoles | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | Hypoglycemic Agents | Type 2 | MEDICAL AND HEALTH SCIENCES | Drug | Hypertension | drug therapy | complications | Diabetes Mellitus | classification | etiology | adverse effects | Dose-Response Relationship | therapeutic use | Diabetic Retinopathy
Journal Article